In other locations and the European Union, where the remainders of Eckert & Ziegler’s production sites are located, so far no closing orders have been issued. In the opinion of the Management Board, however, the situation in almost all places is similar to California, not only for the live saving cancer treatment devices or radiopharmaceuticals that are manufactured in these other locations, but also for services and industrial products. Cobalt irradiation sources, seemingly just a technical component, are for example needed for the gamma sterilization of medical devices and lately see a soaring demand.
“The group’s economic performance will nevertheless be affected by the global governmental reactions to the corona crisis” cautions the CEO of the group, Dr. Andreas Eckert. “The turmoil caused by social thinning-out measures, curfews, school closures, or travel restrictions has already led to the delay or cancellation of orders and increased cost. Furthermore, the widespread paralyzation of public institutions and the interruptions of well-established routines may influence the ability to implement countermeasures swiftly.”
The group will provide further details on the 2020 outlook together with the details of the 2019 annual report on 31 March 2020.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
